Date: 2012-05-30
Type of information: R&D agreement
Compound: novel targets in the field of allergic diseases
Company: Galapagos's UK subsidiary BioFocus (Belgium) Ono Pharmaceutical (Japan)
Therapeutic area: Respiratory diseases - Inflammatory diseases - Allergic diseases - Dermatological diseases
Type agreement: R&D
Action mechanism:
Disease: novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma
Details: Ono and Galapagos subsidiary BioFocus have signed an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma. In the new agreement, Galapagos’ service division BioFocus will use its SilenceSelect® platform to deliver validated targets to Ono. Ono aims to find modulators for these targets and generate novel drug candidates. SilenceSelect® is a platform technology which utilizes human primary cell assays with ribonucleic acid (RNA) interference (RNAi) through proprietary adenoviral technology to find novel targets. RNAi is a technology that controls the activity of specific genes by introducing small double-stranded RNA fragments into cells.
Financial terms: Financial details were undisclosed.
Latest news:
